Brown Advisory Securities LLC Sells 169 Shares of DexCom, Inc. (NASDAQ:DXCM)

Brown Advisory Securities LLC cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCMGet Rating) by 26.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 460 shares of the medical device company’s stock after selling 169 shares during the period. Brown Advisory Securities LLC’s holdings in DexCom were worth $235,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DXCM. Van ECK Associates Corp bought a new position in shares of DexCom in the 4th quarter valued at $165,000. CWM LLC bought a new position in shares of DexCom in the 4th quarter valued at $153,000. Centaurus Financial Inc. lifted its stake in shares of DexCom by 4.9% in the 4th quarter. Centaurus Financial Inc. now owns 1,172 shares of the medical device company’s stock valued at $629,000 after acquiring an additional 55 shares during the last quarter. FDx Advisors Inc. bought a new position in shares of DexCom in the 4th quarter valued at $473,000. Finally, Pinnacle Financial Partners Inc. bought a new position in shares of DexCom in the 4th quarter valued at $268,000. 93.26% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Chad Patterson sold 777 shares of the firm’s stock in a transaction dated Monday, May 9th. The shares were sold at an average price of $342.77, for a total value of $266,332.29. Following the transaction, the executive vice president now owns 13,675 shares of the company’s stock, valued at approximately $4,687,379.75. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, EVP Chad Patterson sold 777 shares of the firm’s stock in a transaction dated Monday, May 9th. The shares were sold at an average price of $342.77, for a total value of $266,332.29. Following the transaction, the executive vice president now owns 13,675 shares of the company’s stock, valued at approximately $4,687,379.75. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Steven Robert Pacelli sold 250 shares of the firm’s stock in a transaction dated Tuesday, May 24th. The shares were sold at an average price of $296.33, for a total transaction of $74,082.50. Following the completion of the transaction, the director now directly owns 35,175 shares in the company, valued at approximately $10,423,407.75. The disclosure for this sale can be found here. Insiders sold a total of 3,627 shares of company stock worth $676,977 in the last three months. Company insiders own 0.41% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on DXCM. Raymond James dropped their price target on DexCom from $134.50 to $121.50 in a research note on Friday, April 29th. Sanford C. Bernstein began coverage on DexCom in a report on Friday, July 15th. They issued an “outperform” rating and a $105.00 price objective for the company. Robert W. Baird decreased their price objective on DexCom from $115.00 to $97.00 in a report on Friday, July 29th. Piper Sandler decreased their price objective on DexCom from $120.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, July 29th. Finally, Morgan Stanley decreased their price objective on DexCom from $91.00 to $83.00 and set an “equal weight” rating for the company in a report on Friday, July 29th. Two equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $115.23.

DexCom Stock Performance

Shares of DXCM opened at $89.09 on Friday. The company has a debt-to-equity ratio of 0.87, a current ratio of 4.72 and a quick ratio of 4.30. The stock has a 50-day moving average of $86.60 and a 200-day moving average of $98.48. The company has a market cap of $34.97 billion, a PE ratio of 185.61, a P/E/G ratio of 3.58 and a beta of 1.03. DexCom, Inc. has a one year low of $66.89 and a one year high of $164.86.

DexCom (NASDAQ:DXCMGet Rating) last issued its earnings results on Thursday, July 28th. The medical device company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.02). The firm had revenue of $696.20 million during the quarter, compared to analyst estimates of $709.33 million. DexCom had a net margin of 7.47% and a return on equity of 11.79%. The business’s quarterly revenue was up 17.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.19 earnings per share. On average, equities research analysts predict that DexCom, Inc. will post 0.8 EPS for the current fiscal year.

DexCom Profile

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

See Also

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMGet Rating).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.